Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564354 · ClinicalTrials.gov registry record · Phase 1
Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
A Phase 1 study, sponsored by ProQR Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02564354 is a Phase 1 study that has completed, run by ProQR Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT02564354, a Phase 1 study, has completed, sponsored by ProQR Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Exploratory proof of concept study to determine whether intranasal administration of QR-010 in subjects with cystic fibrosis, homozygous or compound heterozygous for the ΔF508 mutation, can increase the function of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
Interventions
- DRUG QR-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564354
The ClinicalTrials.gov registry entry for NCT02564354 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProQR Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QR-010 is the first listed.
NCT02564354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564354 about?
NCT02564354 is a clinical study titled "Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation". Exploratory proof of concept study to determine whether intranasal administration of QR-010 in subjects with cystic fibrosis, homozygous or compound heterozygous for the ΔF508 mutation, can increase the function of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
What is the current status of trial NCT02564354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02564354?
The interventions under investigation include: QR-010 (DRUG).
Who is sponsoring clinical trial NCT02564354?
This trial is sponsored by ProQR Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.